Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,014 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs.
Johnson-Huang LM, Pensabene CA, Shah KR, Pierson KC, Kikuchi T, Lentini T, Gilleaudeau P, Sullivan-Whalen M, Cueto I, Khatcherian A, Hyder LA, Suárez-Fariñas M, Krueger JG, Lowes MA. Johnson-Huang LM, et al. Among authors: kikuchi t. PLoS One. 2012;7(2):e30308. doi: 10.1371/journal.pone.0030308. Epub 2012 Feb 10. PLoS One. 2012. PMID: 22348003 Free PMC article. Clinical Trial.
Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris.
Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I, Khatcherian A, Novitskaya I, Wittkowski KM, Krueger JG. Chamian F, et al. Among authors: kikuchi t. Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2075-80. doi: 10.1073/pnas.0409569102. Epub 2005 Jan 25. Proc Natl Acad Sci U S A. 2005. PMID: 15671179 Free PMC article. Clinical Trial.
Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a).
Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R, Novitskaya I, Carbonaro H, Cardinale I, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Wittkowski KM, Papp K, Garovoy M, Dummer W, Steinman RM, Krueger JG. Lowes MA, et al. Among authors: kikuchi t. Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19057-62. doi: 10.1073/pnas.0509736102. Proc Natl Acad Sci U S A. 2005. PMID: 16380428 Free PMC article.
Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness.
Guttman-Yassky E, Vugmeyster Y, Lowes MA, Chamian F, Kikuchi T, Kagen M, Gilleaudeau P, Lee E, Hunte B, Howell K, Dummer W, Bodary SC, Krueger JG. Guttman-Yassky E, et al. Among authors: kikuchi t. J Invest Dermatol. 2008 May;128(5):1182-91. doi: 10.1038/jid.2008.4. Epub 2008 Jan 31. J Invest Dermatol. 2008. PMID: 18239614 Free article. Clinical Trial.
Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin.
Vugmeyster Y, Kikuchi T, Lowes MA, Chamian F, Kagen M, Gilleaudeau P, Lee E, Howell K, Bodary S, Dummer W, Krueger JG. Vugmeyster Y, et al. Among authors: kikuchi t. Clin Immunol. 2004 Oct;113(1):38-46. doi: 10.1016/j.clim.2004.06.001. Clin Immunol. 2004. PMID: 15380528
Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.
Chamian F, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I, Khatcherian A, Novitskaya I, Wittkowski KM, Krueger JG, Lowes MA. Chamian F, et al. Among authors: kikuchi t. J Transl Med. 2007 Jun 7;5:27. doi: 10.1186/1479-5876-5-27. J Transl Med. 2007. PMID: 17555598 Free PMC article. Clinical Trial.
3,014 results